CliffBio
small molecule

IBSRELA

TENAPANOR HYDROCHLORIDE

Loss of exclusivityNovember 2042latest FDA-listed patent expiry
CompanyArdelyx →See this company's full patent-cliff portfolio

Drug detail

Brand nameIBSRELA
Active ingredientTENAPANOR HYDROCHLORIDE
StrengthEQ 50MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 2019
Marketing statusRX

Listed patents

PatentExpiresType
12539299November 2042product
8541448August 2033substance, product
9006281May 2030use U-2626
9408840December 2029use U-2626
8969377December 2029substance, product
12016856December 2029substance, product

More from Ardelyx

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.